Literature DB >> 15292101

Male hormonal contraception: suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in chinese men.

You-Lun Gui1, Chang-Hai He, John K Amory, William J Bremner, E-Xiang Zheng, Jie Yang, Pei-Juan Yang, Er-Sheng Gao.   

Abstract

Monthly injections of testosterone undecanoate (TU) act as a male contraceptive by reversibly suppressing spermatogenesis to azoospermia or severe oligoazoospermia in 95% of Chinese men. In 5% of Chinese men, however, monthly TU administered alone fails to suppress spermatogenesis into contraceptive ranges, or sperm "rebound," leading to occurrences of pregnancy during treatment. Since combinations of progestins and androgens are associated with greater degrees of sperm suppression in white men, we hypothesized that the combination of TU and the progestin levonorgestrel (LNG) would result in improved spermatogenic suppression in Chinese men. Sixty-two healthy Chinese men were randomly assigned to one of the following 3 regimens: group I (n = 21) received 4 LNG rods (75 mg each), which were followed 4 weeks later by 500 mg of TU by intra-muscular (IM) injection every 8 weeks for 24 weeks; group II (n = 20) received 4 LNG implants, which were followed 4 weeks later by 1000 mg of TU by IM injection every 8 weeks for 24 weeks; and group III (n = 21) received TU 1000 mg by IM injection every 8 weeks for 24 weeks. Sperm counts, serum testosterone (T), luteinizing hormone, follicle-stimulating hormone, and LNG were measured every 2 weeks before, during, and after treatment. During treatment, group II demonstrated a trend toward a greater attainment of azoospermia than groups I and III (90% vs 62% [group I] vs 67% [group III]; P =.09). Attainments of either azoospermia or oligozoospermia (sperm density, <3 x 10(6)/mL) were 95%, 100%, and 86% for groups I, II, and III, respectively (P >.05 for comparisons between groups). Spermatogenesis in all subjects returned to the normal range after the implants were removed. No serious adverse events and no significant changes in serum chemistry occurred during the study. These results demonstrate that the combination of IM injections of high-dose TU every 2 months and LNG implants is associated with marked suppression of spermatogenesis in Chinese men. The combination of high-dose TU every 2 months and LNG implants is a promising candidate for future large-scale efficacy studies of hormonal male contraception in Chinese men.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15292101     DOI: 10.1002/j.1939-4640.2004.tb02846.x

Source DB:  PubMed          Journal:  J Androl        ISSN: 0196-3635


  10 in total

1.  Simultaneous quantification of steroids in rat intratesticular fluid by HPLC-isotope dilution tandem mass spectrometry.

Authors:  Alissa Renne; Lindi Luo; Jonathan Jarow; William W Wright; Terry R Brown; Haolin Chen; Barry R Zirkin; Marlin D Friesen
Journal:  J Androl       Date:  2011-10-20

Review 2.  Male hormonal contraception: potential risks and benefits.

Authors:  Niloufar Ilani; Ronald S Swerdloff; Christina Wang
Journal:  Rev Endocr Metab Disord       Date:  2011-06       Impact factor: 6.514

Review 3.  Progress and prospects in male hormonal contraception.

Authors:  John K Amory
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2008-06       Impact factor: 3.243

Review 4.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

Review 5.  Beyond the Condom: Frontiers in Male Contraception.

Authors:  Mara Y Roth; John K Amory
Journal:  Semin Reprod Med       Date:  2016-03-04       Impact factor: 1.303

6.  Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis.

Authors:  Peter Y Liu; Ronald S Swerdloff; Bradley D Anawalt; Richard A Anderson; William J Bremner; Joerg Elliesen; Yi-Qun Gu; Wendy M Kersemaekers; Robert I McLachlan; M Cristina Meriggiola; Eberhard Nieschlag; Regine Sitruk-Ware; Kirsten Vogelsong; Xing-Hai Wang; Frederick C W Wu; Michael Zitzmann; David J Handelsman; Christina Wang
Journal:  J Clin Endocrinol Metab       Date:  2008-02-26       Impact factor: 5.958

Review 7.  Male hormonal contraception: looking back and moving forward.

Authors:  M Y Roth; S T Page; W J Bremner
Journal:  Andrology       Date:  2015-10-09       Impact factor: 3.842

8.  Reversible infertility associated with testosterone therapy for symptomatic hypogonadism in infertile couple.

Authors:  Jeong Kyoon Bang; Jung Jin Lim; Jin Choi; Hyung Jae Won; Tae Ki Yoon; Jae Yup Hong; Dong Soo Park; Seung-Hun Song
Journal:  Yonsei Med J       Date:  2013-05-01       Impact factor: 2.759

Review 9.  Testosterone depot injection in male hypogonadism: a critical appraisal.

Authors:  Aksam A Yassin; Mohamed Haffejee
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

Review 10.  Male contraception.

Authors:  Jing Chao; Stephanie T Page; Richard A Anderson
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2014-06-05       Impact factor: 5.237

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.